XyloCor Therapeutics is focused on improving the lives of people with cardiovascular disease through our commitment to advancing the science of gene therapy.
Press Release: June 28, 2022
XyloCor Therapeutics Achieves Target Enrollment in Phase 2 EXACT Study of XC001 Novel Gene Therapy for Ischemic Heart Disease
More >>
XyloCor’s proprietary products address significant unmet clinical needs in cardiovascular disease.
More >>
XyloCor’s products are enabled by proprietary gene therapy technologies from Weill Cornell Medical College.
More >>